000141672 001__ 141672
000141672 005__ 20240229105128.0
000141672 0247_ $$2doi$$a10.1080/15592294.2018.1514853
000141672 0247_ $$2pmid$$apmid:30152726
000141672 0247_ $$2pmc$$apmc:PMC6224222
000141672 0247_ $$2ISSN$$a1559-2294
000141672 0247_ $$2ISSN$$a1559-2308
000141672 0247_ $$2altmetric$$aaltmetric:47216750
000141672 037__ $$aDKFZ-2018-01943
000141672 041__ $$aeng
000141672 082__ $$a610
000141672 1001_ $$0P:(DE-He78)0c11091f5d6e883a9b6029e4ccea5d5c$$aGao, Xu$$b0$$eFirst author$$udkfz
000141672 245__ $$aLeukocyte telomere length and epigenetic-based mortality risk score: associations with all-cause mortality among older adults.
000141672 260__ $$aAustin, Tex.$$bLandes Bioscience$$c2018
000141672 3367_ $$2DRIVER$$aarticle
000141672 3367_ $$2DataCite$$aOutput Types/Journal article
000141672 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1542895904_13183
000141672 3367_ $$2BibTeX$$aARTICLE
000141672 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141672 3367_ $$00$$2EndNote$$aJournal Article
000141672 520__ $$aTelomere length (TL) has been established as a biomarker of aging and aging-related health outcomes, but showed only a weak or inconsistent association with all-cause mortality in previous epidemiological studies. Recently, an epigenetic 'mortality risk score' (MS) based on whole blood DNA methylation at 10 mortality-related CpG sites has been demonstrated to be strongly related to all-cause mortality at the population level. This study aimed to address the association between TL and this MS, and to assess and compare their associations with all-cause mortality. The MS was derived from the DNA methylation profiles measured by Illumina Human Methylation450K Beadchip and TL was measured by quantitative PCR at baseline among 1517 participants aged 50-75 of the German ESTHER cohort study. In cross-sectional bi- and multivariable analyses, the MS was strongly associated and showed monotonic dose-response relationships with TL (p-values <0.05). However, only the MS but not TL was associated with all-cause mortality during a median follow-up of 12.5 years. After controlling for potential covariates and TL, hazard ratios (95% CI) for all-cause mortality for low, moderate and high levels of the MS defined by 1, 2-5 and >5 CpG sites with aberrant methylation were 2.24 (1.13-4.41), 3.31 (1.76-6.22) and 6.33 (3.22-12.41) compared to a MS of 0, respectively. Our investigation shows that the epigenetic-based MS is strongly associated with TL, a broadly accepted aging biomarker, and at the same time shows much stronger associations with all-cause mortality than the latter.
000141672 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141672 588__ $$aDataset connected to CrossRef, PubMed,
000141672 7001_ $$0P:(DE-He78)6a8f87626cb610618a60d742677284cd$$aZhang, Yan$$b1$$udkfz
000141672 7001_ $$0P:(DE-He78)1b59582b6c05ac4e57aa8b90dd9667f9$$aMons, Ute$$b2$$udkfz
000141672 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$eLast author$$udkfz
000141672 773__ $$0PERI:(DE-600)2248598-3$$a10.1080/15592294.2018.1514853$$gVol. 13, no. 8, p. 846 - 857$$n8$$p846 - 857$$tEpigenetics$$v13$$x1559-2308$$y2018
000141672 909CO $$ooai:inrepo02.dkfz.de:141672$$pVDB
000141672 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0c11091f5d6e883a9b6029e4ccea5d5c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141672 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6a8f87626cb610618a60d742677284cd$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141672 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1b59582b6c05ac4e57aa8b90dd9667f9$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000141672 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000141672 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141672 9141_ $$y2018
000141672 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEPIGENETICS-US : 2017
000141672 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141672 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141672 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141672 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141672 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141672 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141672 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141672 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141672 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141672 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000141672 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000141672 9201_ $$0I:(DE-He78)M050-20160331$$kM050$$lKrebsprävention$$x2
000141672 980__ $$ajournal
000141672 980__ $$aVDB
000141672 980__ $$aI:(DE-He78)C070-20160331
000141672 980__ $$aI:(DE-He78)G110-20160331
000141672 980__ $$aI:(DE-He78)M050-20160331
000141672 980__ $$aUNRESTRICTED